化合物 MMAE-d8|T10948|TargetMol

價(jià)格	￥9120	￥18200
包裝	1mg	5mg

最小起訂量	1mg
發(fā)貨地	上海
更新日期	2024-12-12

QQ交談微信洽談

產(chǎn)品詳情

中文名稱:化合物 MMAE-d8	英文名稱:MMAE-d8
CAS:2070009-72-0	品牌: TargetMol
產(chǎn)地: 美國(guó)	保存條件: Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
純度規(guī)格: 98%	產(chǎn)品類別: 抑制劑
貨號(hào): T10948

Product Introduction

Bioactivity

名稱	MMAE-d8
描述	D8-MMAE (D8-Monomethyl auristatin E) is an effective mitotic inhibitor and tubulin inhibitor, deuterated MMAE.
體外活性	Antibody-drug conjugates (ADC) contain targeted antibodies with effective small molecule payloads. The ADC is produced against different receptors on the anaplastic large cell lymphoma L-82 line, but delivers the same cytotoxic payload (monomethyl auristatin E, MMAE). ADC-mediated cytotoxicity is not related to target expression or drug: antibody ratio. LC-MS was used to measure the concentration of MMAE in the L-82 tumor parallel cohort by the same treatment protocol. Although there was no difference in tumor volume between the treatment groups 3 days after administration, intratumoral MMAE measurements showed two patterns. First, the MMAE concentration in the tumor increases in proportion to the ADC dose, which corresponds to stronger antitumor activity. Second, intra-tumor MMAE concentrations obtained after treatment with cOKT9-vcMMAE and cAC10-vcMMAE were similar at each dose, which is consistent with the observation that tumors responded similarly to these two ADCs.
體內(nèi)活性	In tumor xenograft models, the MMAE concentration in the tumor is always correlated with the degree of tumor growth inhibition. IHC analysis showed that tumors that were not combined with control treatment consisted of CD30 + and CD30 cells, presumably because they did not kill CD30 + or CD30- Karpas 299 cells. Only CD30-cells were found in tumors treated with cAC10-vcMMAF, indicating that cAC10-vcMMAF eliminated most CD30 + cells. Interestingly, at the end of the study, two tumors recurring from the treatment of cAC10-vcMMAE were also found to be CD30-, indicating that in the remaining two tumors, a small portion of CD30-cells may have escaped bystanders Kill.
存儲(chǔ)條件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	DMSO : 100 mg/mL (137.74 mM), Sonication is recommended.
關(guān)鍵字	MMAE-d-8 \| MMAE d8 \| MMAEd8 \| MMAE-d8
相關(guān)產(chǎn)品	Fluticasone (propionate) \| Doxorubicin hydrochloride \| Aldoxorubicin hydrochloride \| Dexamethasone acetate \| Daunorubicin hydrochloride \| Camptothecin \| Paclitaxel \| Budesonide \| Exatecan \| Monomethyl auristatin E \| Methotrexate \| Mertansine

關(guān)鍵字： D8-MMAE|||D8-Monomethyl auristatin E|TargetMol

公司簡(jiǎn)介

TargetMol Chemicals Inc. 總部位于馬薩諸塞州波士頓，致力于為全球生化領(lǐng)域科學(xué)家的研究提供專業(yè)的產(chǎn)品和服務(wù)。TargetMol?品牌的客戶群分布于40多個(gè)國(guó)家和地區(qū)，已發(fā)展成為全球知名的化合物庫(kù)和小分子化合物研究供應(yīng)商。 TargetMol?可提供160多種滿足不同需求的化合物庫(kù)，以及多種類型的生化試劑產(chǎn)品，包括12000多種抑制劑、16000多種天然產(chǎn)物和各類多肽、抗體、生命科學(xué)試劑盒等，此外，我們還建設(shè)有CADD（計(jì)算機(jī)輔助藥物設(shè)計(jì)）研究中心、藥理實(shí)驗(yàn)室、藥化合成平臺(tái)三大技術(shù)中心，全方位滿足客戶的定制需求。憑借我們優(yōu)質(zhì)的產(chǎn)品和服務(wù)、快速高效的全球供應(yīng)鏈和專業(yè)的技術(shù)支持，我們將有效幫助您縮短研發(fā)周期，取得更成功的結(jié)果。

成立日期	2013-04-18 （12年）	注冊(cè)資本	566.265100萬人民幣
員工人數(shù)	100-500人	年?duì)I業(yè)額	￥ 1億以上
主營(yíng)行業(yè)	天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù)	經(jīng)營(yíng)模式	貿(mào)易,工廠,試劑,定制,服務(wù)

TargetMol中國(guó)（陶術(shù)生物）

VIP 3年

公司成立：12年
注冊(cè)資本：566.265100萬人民幣
企業(yè)類型：有限責(zé)任公司(自然人投資或控股)
主營(yíng)產(chǎn)品：小分子抑制劑、藥物篩選化合物庫(kù)、藥物篩選等
公司地址：靜安區(qū)江場(chǎng)三路238號(hào)8樓

進(jìn)入店鋪

詢盤

店內(nèi)推薦

LJP-1586鹽酸鹽|T8857|TargetMol

￥779

化合物 Leteprinim potassium|T32658|TargetMol

￥2830

化合物 γ-Linolenic acid ethyl ester|T41235|TargetMol

￥1120